Shares of Novo Nordisk on Monday fell 10% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet it…
Wells Fargo recently adjusted their price target for Novo Nordisk (NVO), following an agreement that underscores the value of Septerna’s platform. This new part